Literature DB >> 11406733

The role of low-molecular-weight heparins in the management of unstable angina and non-ST-segment elevation myocardial infarction.

M Cohen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11406733     DOI： 10.1023/a:1011284902244

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  27 in total

1.  Combination therapy with tirofiban and enoxaparin in acute coronary syndromes.

Authors:  M Cohen; P Théroux; S Weber; P Laramée; T Huynh; S Borzak; J G Diodati; I B Squire; L I Deckelbaum; A R Thornton; K E Harris; F L Sax; M W Lo; H D White
Journal:  Int J Cardiol       Date:  1999-12-01       Impact factor: 4.164

Review 2.  Low molecular weight heparin: laboratory properties and clinical evaluation. A review.

Authors:  J Hirsh; M N Levine
Journal:  Eur J Surg Suppl       Date:  1994

3.  Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.

Authors: 
Journal:  N Engl J Med       Date:  1997-06-12       Impact factor: 91.245

4.  Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction].

Authors:  D B Mark; P A Cowper; S D Berkowitz; L Davidson-Ray; E R DeLong; A G Turpie; R M Califf; B Weatherley; M Cohen
Journal:  Circulation       Date:  1998-05-05       Impact factor: 29.690

Review 5.  Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE guys finish first".

Authors:  D J Kereiakes; E Fry; W Matthai; A Niederman; L Barr; B Brodie; J Zidar; P Casale; G Christy; D Moliterno; R Lengerich; T Broderick; T Shimshak; M Cohen
Journal:  J Invasive Cardiol       Date:  2000-02       Impact factor: 2.022

Review 6.  The emerging role of low-molecular-weight heparin and antiplatelet therapies in the cardiac catheterization laboratory.

Authors:  E Deutsch
Journal:  Am Heart J       Date:  1999-12       Impact factor: 4.749

7.  Low-molecular-weight heparins in coronary stenting (the ENTICES trial). ENoxaparin and TIClopidine after Elective Stenting.

Authors:  J P Zidar
Journal:  Am J Cardiol       Date:  1998-09-10       Impact factor: 2.778

8.  Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).

Authors: 
Journal:  Eur Heart J       Date:  1999-11       Impact factor: 29.983

9.  Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina.

Authors:  P Théroux; D Waters; S Qiu; J McCans; P de Guise; M Juneau
Journal:  Circulation       Date:  1993-11       Impact factor: 29.690

10.  Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators.

Authors: 
Journal:  Circulation       Date:  1994-10       Impact factor: 29.690
View more
  2 in total

1.  Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis.

Authors:  Paola Sanchez-Pena; Jean-Sébastien Hulot; Saïk Urien; Annick Ankri; Jean-Philippe Collet; Rémi Choussat; Philippe Lechat; Gilles Montalescot
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

2.  Thromboelastography for the monitoring of the antithrombotic effect of low-molecular-weight heparin after major orthopedic surgery.

Authors:  Nilgün Tekkesin; Mustafa Tekkesin; Güzin Kaso
Journal:  Anatol J Cardiol       Date:  2015-11       Impact factor: 1.596
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.